Are you a hematologist or oncologist treating patients with multiple myeloma? If so, this 90-minute webinar is for you.
This high-impact educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.
At the conclusion of this educational activity, you will be able to:
1. Understand the types of patients who should be considered for novel immune based strategies including bispecific T cell engagers and CAR T cell therapy.
2. Understand the differences between TCEs, antibody drug conjugates, and CAR T cell process and data for appropriate care of the patient prior to consideration for these therapies.
3. Understand toxicities and their management post-novel immune strategies.
At the conclusion of this educational activity, you will be able to:
1. Understand the types of patients who should be considered for novel immune based strategies including bispecific T cell engagers and CAR T cell therapy.
2. Understand the differences between TCEs, antibody drug conjugates, and CAR T cell process and data for appropriate care of the patient prior to consideration for these therapies.
3. Understand toxicities and their management post-novel immune strategies.
Registration is complimentary.
Date & Time
West Coast Webinar
Wednesday, April 10, 2024
6:00-7:30 PM PST.
Wednesday, April 10, 2024
6:00-7:30 PM PST.
The International Myeloma Society gratefully acknowledges the following organization for their support of the workshop:
This activity is supported by an independent grant from Bristol Myers Squibb
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
About the International Myeloma Society
The International Myeloma Society is a professional, scientific, and medical society established to
bring together clinical and experimental scientists involved in the study of myeloma.
The purpose of this society is to promote research, education, clinical studies (including diagnosis
and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical
investigators in the field along with physicians and other healthcare practitioners.
bring together clinical and experimental scientists involved in the study of myeloma.
The purpose of this society is to promote research, education, clinical studies (including diagnosis
and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical
investigators in the field along with physicians and other healthcare practitioners.